NCT04453085已完成1 期
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 6
- 主要终点
- Number of participants with Adverse Events
研究概览
简要总结
Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 (NCT04227600) for the treatment of MPS I
详细描述
Patients who have completed the Part2 of JR-171-101 study (NCT04227600) and fulfill all eligibility criteria can be enrolled in this JR-171-102 study. In the JR-171-102 study, subjects will receive either 2.0 or 4.0 mg/kg/week of JR-171 intravenously at the same doses received at Week 12 of the JR-171-101 study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have completed the Part 2 of JR-171-101 study
- •A patient from whom written informed consent can be obtained. If the patient is aged under 18 years (20 years in case of Japan) at the time of assent or willingness to participate in the study cannot be confirmed due to MPS I-related intellectual disability, informed permission from the patient's legally acceptable representative (e.g., his/her parents or guardians) need to be obtained instead of his/her consent. Even in this case, written informed consent should be obtained from the patient, wherever possible
- •Female patient or male patient whose co-partners is of child-bearing potential agree to use a medically accepted, highly effective method of contraception, such as spermatocidal gel plus condom, an intrauterine device or oral contraceptives until one month after the final administration.
排除标准
- •A patient who is unable to perform the study procedures, except for 6-minute walk test, neurocognitive testing, BVMT-R, HVLT-R, and T.O.V.A.
- •Judged by the principal investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumbar puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process
- •Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or hypersensitivity to any drugs
- •Otherwise judged by the principal investigator or subinvestigator to be ineligible to participate in the study in consideration of patient's safety
研究组 & 干预措施
Dose level 1
Experimental
2.0 mg/kg/week
干预措施: JR-171 (Drug)
Dose level 2
Experimental
4.0 mg/kg/week
干预措施: JR-171 (Drug)
结局指标
主要结局
Number of participants with Adverse Events
时间窗: 156 weeks
Infusion associated reaction (IAR)
Incidence of abnormal vital signs
时间窗: 156 weeks
Body weight
Incidence of abnormal EKG readings
时间窗: 156 weeks
Incidence of abnormal laboratory test results
时间窗: 156 weeks
Urinalysis
次要结局
- Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid (CSF)(Weeks 26, 52, 104, 156)
- Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid(Weeks 26, 52, 104, 156)
- CSF opening pressure(Weeks 26, 52, 104, 156)
- Change From Baseline in Heparan Sulfate Levels in Urinary(Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156)
- Change From Baseline in Dermatan Sulfate Levels in Urinary(Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156)
- Change From Baseline in Heparan Sulfate Levels in Serum(Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156)
- Change From Baseline in Dermatan Sulfate Levels in Serum(Weeks 13, 26, 39, 52, 65, 78, 91, 104, 130, 156)
- Change From Baseline in Liver Volume(Weeks 13, 26, 52, 78, 104, 156)
- Change From Baseline in Spleen Volume.(Weeks 13, 26, 52, 78, 104, 156)
- Change From Baseline in Echocardiography.(Weeks 13, 26, 52, 78, 104, 156)
- Change From Baseline in 6-minute Walk Test Distance.(Weeks 13, 26, 52, 78, 104, 156)
- Changes from baseline in cognitive age equivalent score of neurocognitive testing(Weeks 52, 104, 156)
- Changes from baseline in outcome of adaptive behavioral function(Weeks 52, 104, 156)
- Changes from baseline in outcome of the Brief Visuospatial Memory Test-Revised(Weeks 13, 26, 52, 78, 104, 130, 156)
- Changes from baseline in outcome of the Hopkins Verbal Learning Test-Revised(Weeks 13, 26, 52, 78, 104, 130, 156)
- Changes from baseline in outcome of the Test of Variables of Attention(Weeks 13, 26, 52, 78, 104, 130, 156)
- Changes from baseline in outcome of the Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)(Weeks 13, 26, 52, 104 156)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
1 期
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type IMucopolysaccharidosis IJPRN-jRCT2051210040Kawashima Satoshi14
进行中（未招募）
2 期
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis IIMucopolysaccharidosis IINCT03708965JCR Pharmaceuticals Co., Ltd.19
Enrolling By Invitation
3 期
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) SubjectsMucopolysaccharidosis IINCT05594992JCR Pharmaceuticals Co., Ltd.80
已完成
2 期
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisNCT05364554Janssen Research & Development, LLC227
进行中（未招募）
2 期
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type IIMucopolysaccharidosis IINCT04348136JCR Pharmaceuticals Co., Ltd.27